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DNA methylation is the best understood heritable gene regulatory mechanism that
does not involve direct modification of DNA sequence itself. Cells with different methy-
lation profiles (over temporal or micro-environmental dimensions) may exhibit different
phenotypic properties. In cancer, heterogeneity across cells in the tumor microenviron-
ment presents significant challenges to treatment. In particular, epigenetic heterogeneity
is discernible among tumor cells, and it is believed to impact the growth properties and
treatment resistance of tumors.
Existing computational methods used to study the epigenetic composition of cell
populations are based on the analysis of DNA methylation modifications at multiple con-
secutive genomic loci spanned by single DNA sequencing reads. These approaches have
yielded great insight into how cell populations differ epigenetically across different tis-
sues. However, they only provide a general summary of the epigenetic composition of
these cell populations without providing cell-specific methylation patterns over longer
genomic spans to perform a comprehensive analysis of the epigenetic heterogeneity of
cell populations.
In this dissertation, we address this challenge by proposing two computational
methods called methylFlow and MCFDiff. In methylFlow, we propose a novel method
based on network flow algorithms to reconstruct cell-specific methylation profiles using
reads obtained from sequencing bisulfite-converted DNA. We reveal the methylation pro-
file of underlying clones in a heterogeneous cell population including the methylation
patterns and their corresponding abundance within the population.
In MCFDiff, we propose a statistical model that leverages the identified cell-specific
methylation profiles (from methylFlow) to determine regions of differential methylation
composition (RDMCs) between multiple phenotypic groups, in particular, between tumor
and paired normal tissue. In MCFDiff, we can systematically exclude the tumor tissue
impurities and increase the accuracy in detecting the regions with differential methylation
composition in normal and tumor samples. Profiling the changes between normal and
tumor samples according to the reconstructed methylation profile of underling clone in
different samples leads us to the discovery of de novo epigenetic markers and a better
understanding about the effect of epigenetic heterogeneity in cancer dynamics from the
initiation, progression to metastasis, and relapse.
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DNA as the molecule that encodes the genetic information of life is very stable and
robust. During cell division, daughter cells inherit almost exact DNA sequence. How-
ever, scientists observed that cells with identical genomic information may have different
phenotypic properties. Conard Waddington, in 1939, first introduced the concept of epi-
genetics [Wad42] to describe the interaction between the cell and its environment. Today,
epigentics refers to any heritable modification of DNA (e.g methylation) that does not
change the genome [DAB09]. These modifications affect gene activity and leads to emer-
gence of cells with different phenotypes. For example, differences in monozygotic twins
are partially explained by epigenetic modifications on genome [PGK+03]. However, epi-
genetic modifications are also frequently associated in tumor cells to the modulation of
their malignant transcriptome [Ced88]. Different phenotypic properties in different tumor
tissues and cell types (inter-tumor heterogeneity), and also the subclonal diversity within
a single tumor tissue (intra-tumor heterogeneity) correspond to different epigenetic mod-
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ifications to the genome [BMBS13]. EWAS (Epigenome-Wide Association Studies) have
investigated the genome-wide differences of the epigenetic markers in different individ-
uals with various diseases or traits [RDBB11]. Epigenome-Wide Association Studies
are carried out under the assumption that methylation modifications vary by time due to
environmental stimuli. These modifications can change the healthy regulation of gene
expression to a disease pattern in cancerous cells.
Among different types of epigenetic modifications (that are discussed compre-
hensively in Section 1.1), DNA methylation has a significant role in different cancers
[RDBB11,Bir02]. DNA methylation is the covalent binding of a methyl group to the fifth
carbon of cytosine, forming 5-methylcytosine. DNA methylation modification mainly
happens at CpG sites and less frequently in non-CpG context. It regulates gene expres-
sion by recruiting proteins involved in gene repression or by inhibiting the transcription
factor(s) binding to DNA. If the methyl group binding happens at the promoter sites of a
gene, it leads to inactivation of a gene by decreasing its expression. EWAS confirm the
association of numerous cellular processes, such as transcriptional repression [KPW97],
X chromosome inactivation [MSS81], embryonic development [RBL+00], genomic im-
printing [LBJ93], the alteration of chromatin structure, and transposon inactivation with
DNA methylation modification across genome [Jon12]. None of those findings would be
revealed without the development of both experimental and computational approaches.
There are several experimental approaches that are available to catalogue the
genome-wide DNA methylation in epigenome-wide association studies (explained thor-
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oughly in Section 1.2). The main differences between these approaches is the procedure
they use to reveal the methylated sites across genome, their output resolutions, and in-
formation content. The chemical procedure for identifying methylated and unmethylated
sites can be categorized as:
(i) enzyme digestion based methods,
(ii) affinity enrichment based methods,
(iii) bisulfite conversion based methods.
Any of the above procedures could be followed by microarray analysis or sequenc-
ing procedure that implies different outputs as a result. For example in MeDIP-chip, an
affinity enrichment based method [JBE08], the methylation status for a region (depending
on the probes design in the array) is reported. In other methods, the methylation status
at a single base resolution is reported. Such methods include whole genome bisulfite
sequencing techniques (WGBS), reduced representation bisulfite sequencing techniques
(RRBS) [MGB+05a], Illumina’s Infinium Methylation assay [BLB+09] as bisulfite con-
version based approaches, and MeDIP-seq that is an affinity enrichment based method.
The methods that utilize microarrays technology, such as those from Illumina’s HM450K,
report intensity. Intensity reflects the methylation status of the samples within each locus
and is equal to the ratio between the abundance of methylated and unmethylated CpGs.
On the other hand, methods like WGBS, RRBS reflect the methylation status of every
single base and its coverage within the sample. Note that methods followed by sequenc-
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ing techniques usually have higher cost than those followed by microarray techiniques. In
addition, all these techniques could be customized to single-cells, introducing a new gen-
eration of methylation profiling at single-cell resolution. Among those, third-generation
sequencing technology employs sequencing techniques to reveal the methylation profile
of a single cell. This opens the doors to a lot of discoveries about DNA methylation and
also improves our understanding about tumorigenesis and tumor molecular heterogene-
ity. Regardless of the promises, third-generation sequencing technologies still suffer from
higher error rate, higher cost, and lower throughput than second-generation sequencing
technologies like WGBS and RRBS.
The choice of the techniques selected for different analysis is determined based on:
• budget/cost;
• the goal of the study-detecting de novo epigenetic marks or the investigation of
known methylation site;
• the amount, type and quality of the DNA sample(s), number of samples, tissue
types(human, mouse) and specimen amount;
• the required performance in terms of sensitivity and specificity;
• the availability of computational tools.
Among all the techniques, bisulfite sequencing technique is considered the gold
standard method to assess genome-wide DNA methylation in spite of the expense. In
order to detect de novo differential methylation loci or regions when few samples are
available, whole genome bisulfite sequencing technique is the most comprehensive one
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among all existing methods.
With the access to this increasing amount of data retrieved from the above tech-
nologies, different computational approaches are developed to analyze DNA methylation
profiles across various tissues and samples. The analysis are mainly focused on visualiz-
ing and finding differentially methylated loci or regions that are tissue or disease-specific.
In Section 1.3, we review different analytical methods and techniques implemented to find
differential methylation loci and regions as a major problem in EWAS. Most of existing
methods that are concentrated on detecting differentially methylated loci and regions, uti-
lize data at a single base resolution which induces an enormous computational cost on the
algorithm. In addition, most of the existing methods utilize the mean and the variance of
marginal methylation percentage as the input signal to find the differentially methylated
loci or regions. Using this type of data, we lose the spatial correlation of the methylation
status of adjacent CpG sites. In addition, tumor tissue impurity and the sequencing noise
introduce error in the analysis.
In this dissertation, we propose a statistical and computational approach to study the
epigenetic diversity of a heterogenous cell population comprehensively. In our approach
we do not process data at single base resolution and systematically remove the noises due
to tumor impurity and sequencing errors. We (i) reconstruct the methylation profiles of
underlying clones within a heterogeneous cell-type population; and (ii) find the regions
with the significant difference in the composition of the methylation profiles of underly-
ing clones comparing normal and tumor samples by utilizing high-throughput bisulfite-
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converted sequencing data. In fact, our method could be considered as a computational
complement to second-generation sequencing techniques to extract the information about
the DNA methylation profiles at single-cell single-base resolution. It is similar to that of
the third-generation sequencing techniques that reveal the underlying DNA methylation
clones of a heterogenous population while keeping more coverage across different regions
in genome. It also gives an estimate about the abundance of each clone in the heteroge-
nous cell-type population. The latter cannot be obtained by third-generation sequencing
techniques.
1.1 Introduction to Epigenetics
Definition of epigenetic term reveals that we are more than sum of our genes. The
current and our past situations affect the phenotypes of our cells. Epigenetic modifica-
tions generate phenotypic variations within cells with identical DNA sequence. These
variations could be established in genome and even inherited by the next generations.
In order to understand epigenetic modifications, first we need to know about chro-
matin. Chromatin is a condensed structure of genomic DNA and its associated proteins
in the nucleus [Kou07]. Chromatin organizes DNA and wraps it around histone proteins
such that two meters of DNA is packed inside a cell nucleus with a diameter of 6 um. At
the same time chromatin allows DNA to become accessible easily to a variety of proteins
that are involved in DNA transcription, replication and repair processes [Est08, Est07].
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1.1.1 Histone modification
A complex of eight histone proteins that include two copies of each of the core
histones H2A, H2B, H3 and H4 with a stretch of double-stranded DNA (that is wrapped
around the histone core) form a nucleosome. A histone modification is a covalent post-
translational modification (PTM) to histone proteins which includes methylation, phos-
phorylation, acetylation, ubiquitylation, and sumoylation. Amino acid residues in histone
tails can be acetylated (lysines), methylated (lysines) or phosphorylated (serines). All
these modifications can make changes to the shape of the histones and might cause in-
complete unwounding of DNA during replication. If the modified histones carried into
new copies of DNA, they can act as templates for initiation of new histones and alters the
shape of new histones. This is how histone modifications inherited from ancestors.
Studying the effect of different histone modification on genome shows that acety-
lation is generally associated with active transcription [BK11], but for most other modifi-
cations the effects are less predictable. These modifications on histones generally impact
gene expression by altering chromatin structure or recruiting histone modifiers.
1.1.2 DNA methylation
DNA methylation modification is described as binding of methyl group to 5 carbon
of cytosine that occurs most frequently at CpG locations. DNA methylation is an epige-
netic modification that is associated with many of the biological processes such as tran-
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scriptional repression [KPW97], X chromosome inactivation [MSS81], embryonic de-
velopment [RBL+00], genomic imprinting [LBJ93], the alteration of chromatin structure
and transposon inactivation with DNA methylation modification across genome [Jon12].
This process affects the expression of genes by changing the chromatin structure.
Hypermethylation usually causes silencing of genes by inhibiting the binding of tran-
scription factors to the promoter region of genes and in case of hypomethylation, the
expression and production of corresponding proteins increases because the limitations
disappear, and more transcription factors bind to the promoter regions of DNA.
DNA methylation pattern of a cell changes over time and during developmental
stage of cells or it can also remain from the germ line of one of the parents into the zygote.
Hence, the methylation status of some regions is inherited from one parent or the other.
DNA methylation varies from tissue to tissue and from cell to cell, make a population of
cells in a tissue heterogenous. DNA methylation modification is also sequence-context
dependent. It is mainly found in CpG dinucleotides and less in non-CpG regions. In ver-
tebrates 60 − 80% of CpGs are methylated in somatic cells. However in mammals this
ratio is less in CpG islands, i.e. these regions are mainly unmethylated [CFJ+11]. CpG
islands mainly refer to regions that has a length greater than 200bp and a G+C content
greater than 50%. This epigenetic modification is also trans-generationaly heritable. In
each generation, DNA methylation patterns are cleared and established again during de-
velopment except for the trans-generational epigenetic regions that their clearance process
is incomplete.
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All these confirm the necessity of studying DNA methylation modification and pro-
filing its pattern across genome. Also detection of differentially methylated regions helps
to find the association between DNA methylation profiles and disease or tissue specific
expression. In Section 1.2 we overview different experimental methods invented to profile
DNA methylation status of tissue- and disease specific samples.
1.1.3 Chromatin remodeling and nucleosome repositioning
Chromatin remodelling and nucleosome repositioning are other epigenetic mecha-
nisms. Chromatin may have different compaction state. The more compact the chromatin,
the harder it is for transcription factors and other DNA binding proteins to access DNA
and accomplish their job. This is similar to what happens after DNA methylation modifi-
cation and histone modification. The accessibility of some regions across genome alters
due to DNA methylation or histone modifications and chromatin remodeling complexes
that are responsible for changing the compaction state of chromatin. When chromatin is
condensed, and not actively being transcribed it is called heterochromatin. When chro-
matin is more loosely packed, and therefore accessible for transcription factors and other
DNA binding proteins, it is called euchromatin. Loosening up the chromatin allows ac-
cess to DNA and facilitates DNA processes such as transcription, replication and repair.
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Figure 1.1: DNA methylation analysis methods not based on methylation-specific PCR
by Toeng from
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1.2 Experimental methods for DNA methylation profiling
As mentioned above, DNA methylation is one of the epigenetic gene regulatory
mechanism where silencing of gene expression is established by bonding of methyl
groups to DNA at specific genomic regions [HP75]. It is the best understood heritable
mechanism for gene regulation that does not involve direct modification of DNA se-
quence itself. Various studies confirmed the role of DNA methylation modification in
many biological processes and its association in many diseases like diabetes and cancers.
Scientists discovered all these findings by the advent of techniques to profile DNA methy-
lation modifications in various tissues and samples. Previous standard molecular biology
techniques, such as PCR, cloning, and hybridization does not distinguish between methy-
lated and unmethylated cytosines. Initial studies mainly focused on obtaining the methy-
lation status of selected regions and of the genes of interest. Later with the invention of
microarrays and microarray hybridization technology, profiling methylation status scaled
up to the genome-wide level and finally high-throughput sequencing technologies and
new probe design for arrays enable profiling of DNA methylation modifications at single
base resolution. DNA methylation profiling methods use different strategies in revealing
the methylation pattern information. Here, we briefly describe the three aforementioned
categories.
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1.2.1 Enzyme digestion based methods
Enzyme digestion based methods take advantage of those enzymes that are
methylation-sensitives. Some of the restriction enzymes like such as BstUI, HpaII, NotI
and SmaI, cleve only the unmethylated DNA and some like McrBC digest the methylated
DNA.
• MRE-seq In MRE-seq DNA is first digested by methylation-sensitive restriction
enzyme. Then it is sequenced and compared with a non-digested DNA. Deep se-
quencing makes the accurate profiling of DNA methylation at single base resolution
by reporting the relative DNA methylation levels. However, this method has rela-
tively low coverage of the genome with more reliable results at CpG-containing
recognition sites [MNB+10].
• CHARM The comprehensive high-throughput arrays for relative methylation
(CHARM) method [ILAC+08a] uses McrBC, an enzyme that digests methylated
DNA. Then without PCR, and differential hybridization to an array, It uses a new
tiling array specifically designed to maximize the number of assayed CpGs. McrBC
cleave half of the methylated DNA and can detect DNA genome-wide methylation.
1.2.2 Affinity enrichment based methods
The methylated sites of genome can bind to methyl-CpG-binding domain proteins
(MBDs) or antibodies specific for 5mC to enrich methylated DNA regions. Afterwads
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CHIP or sequencing techniques with various platforms are available to profile DNA
methylations. Depending on the technique and the type of protein used to profile the
DNA methylation, the analysis of DNA methylation data and genome coverage varies.
GC content, the extent of DNA amplification, and copy number should be considered in
the subsequent analysis.
• Methylated DNA immunoprecipitation (MeDIP-chip, MeDIP-seq) In Methylated
DNA immunoprecipitation (MeDIP) method [ZWH+14], the methylated DNA is
fractionated using an antibody; then hybridized with a differentially labelled DNA
control to an oligonucleotide array. The relative levels of hypermethylation and
hypomethylation is shown by producing a ratio of green fluorescence to red fluo-
rescence in the array, while immunocaptured DNA and control genomic DNA that
are both labelled with Cy5 and Cy3 fluorescent dyes.
The drawback of MeDIP includes their inability to pinpoint DNA methylation
changes at a single base resolution and its biased toward hypermethylated regions.
It also uses an antibody to 5-methyl-cytosine that is targeting single-stranded DNA.
• MethylCap-seq and MBDCap-seq These techniques use MBD protein which re-
lies on the capacity of MBD proteins to bind specifically to methylated DNA se-
quences. The advantage of this method is the ability of MBD protein to discriminate
between 5mc and 5hmc. Later, microarray (MBD-chip) or sequencing (MBDCap-
seq/MethylCap-seq) [BSM+10] can be used to profile DNA methylation. Also, in
MBDCap approach the methyl-CpG binding domain of the MBD2 protein capture
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double-stranded DNA [SLT09].
1.2.3 Bisulfite conversion based method
DNA is treated with sodium bisulfite to reveal the methylation status of single nu-
cleotides. Sodium bisulfite is a chemical compound that converts unmethylated cytosines
into uracil and methylated cytosines remains the same. Different high-throughput se-
quencing techniques of bisulfite-converted DNA is employed to measure DNA methy-
lation modifications at base-pair level. This approach has led to deeper understanding
of DNA methylation and its role in the development of cells [LPD+09] and many dis-
ease [HTB+11]. In methylation array techniques the bisulfite-treated DNA is hybridized
to arrays that contain predesigned probes to distinguish between methylated and unmethy-
lated Cs. Although whole genome bisulfite sequencing technique has high cost compare
to other methods, bisulfite sequencing quickly considered as the method of choice for
bulk DNA methylation analysis due to its high coverage.
• Whole Genome Bisulfite Sequencing (WGBS)
Whole genome bisulfite sequencing is a next-generation sequencing technology
used to determine the DNA methylation status of single cytosines. DNA is treated
with sodium bisulfite to reveal the methylation status of single nucleotides. Sodium
bisulfite is a chemical compound that converts unmethylated cytosines into uracil
and methylated cytosines remains the same. Converted DNA is then sequenced
in a process similar to standard DNA sequencing methods. The treated DNA is se-
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quenced using non-methylation- specific PCR methods. The thymine appears in se-
quencing instead of uracil representing the unmethylated cytosines while cytosines
sequenced for methyl cytosine residues. Figure 1.1 from (https://en.wikipedia.org)
shows the process. Thus, sequencing the treated DNA with bisulfite reveals infor-
mation about the methylation status of DNA. Various analyses can be performed
to reveal the underlying information of methylation status of DNA among different
samples.
• Reduced Representation Bisulfite Sequencing (RRBS) To cut the cost and reduce
the amount of nucleotides that need to be sequenced, some restriction enzymes,
typically with MspI which is methylation insensitive, are used to cut the genome at
CCGG sites and extract the high CpG density regions of genome. After repairing
the ends, the rest of process follows the same strategy as whole genome bisulfite
sequencing. The CpG-rich segmented DNA is treated by sodium bisulfite and is
sequenced using non-methylation-sensetive PCR methods. In reduced representa-
tion bisulfite sequencing method the number of reads need to be sequenced reduced
dramatically and only 1% of genome is sequenced. The major problem with this
method is that only about 85% of CpG islands and 60% of promoters and CpG
island shores are captured [GSB+11], [LJD+14], [MGB+05a].
• Methylation Arrays . To enable cost-effective DNA methylation profiling, Illumina
offers a robust methylation profiling platform [BLB+09]. Illumina’s Infinium Hu-
manMethylation450 BeadChip (HM450K) protocol involves the treatment of ge-
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nomic DNA with bisulfite and followed by amplification and hybridization of the
converted DNA to arrays containing predesigned probes featuring comprehensive
gene regions and CpG island coverage to distinguish between methylated and un-
methylated Cs.
These method has no PCR and hence no bias toward short fragments. The main
disadvantage of this method is that not every gene of interest is included in the
design of assay.
1.2.4 Single cell DNA methylation profiling
Profiling DNA methylation is extended to the single cell level by recent technolog-
ical innovations. We can categorize different developed strategies in to bisulfite-base and
bisulfite-free methods. Profiling DNA methylation at single cell level give us the opportu-
nity to answer many biological questions and obtain new and deeper insights about some
biological events like tumor heterogeneity and evolution of cancers. These information
could be added to other level of information like gene expression, mutation. One of the
main advantage of single-cell DNA methylation profiling method is its application toward
clinical purposes.
scRRBS [GZW+13, GZG+15], Q-RRBS [WLD+15], MID-RRBS [MRS+18] are
reduced representation bisulfite sequencing based methods. scWGBS [FSN+15], scBS-
seq [SLA+14a], scPBAT [MI14] are whole genome bisulfite sequencing techniques at
single cell level. There are also some bisulfite-free methods like scCGI-seq [HWZ+17],
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RGM [SSS+15], RSMA [KKH+11] and SCRAM [LCB+13, CQBM15].
However, single-cell DNA methylation profiling methods are not able to give a
reliable estimate about the abundance of each cell in a heterogenous cell population which
is also a key factor in DNA methylation profile. They also suffer from higher cost, lower
throughput compared with second generation sequencing methods.
1.3 Analysis of DNA methylation data
Recent technologies made an enormous and ever-growing amount of DNA methyla-
tion data to analyze. Development of statistical models and visualizing DNA methylation
data are the core of analysis to identify DNA methylation differences across different
samples, tissues or different patients with different diseases.
The advent of various techniques provides the opportunity to explore whole genome
DNA CpG methylomes. Here, we focus on methods that analyze DNA methylation pro-
files at single base resolution. Analyzing sequencing based data usually includes align-
ment and post-alignment data processing to more accurately reveal important biological
associations.
1.3.1 Alignment
Many softwares have been developed to align bisulfite sequencing reads. Since un-
methylated cytosines are sequenced as thymines, this complicates the alignment process.
Increasing the number of the mismatches increase noise and error in the alignment. On
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the other hand, there is no reverse compliment for the reads with unmethylated cytosine.
Hence, the followings are some error sources that could affect the quality of mapping
reads.
• Wrong alignment of the reads
• Existence of Single Nucleotide Variants (SNV)
• Sequencing errors
• Bisulfite failure
Given these facts, some new alignment algorithms are developed for aligning
bisulfite sequencing reads, such as BatMeth [LTL+12], Bismark [KA11], Bi-
son [CSRM12], [KRCL+14], bisReadMapper [DPG+12], BSMap [XL09], BRAT and
BRAT-BW [HPL+10], BS-Seeker [CCP10], and BSMooth-align [HLI12a].
1.3.2 Detection of differentially methylated loci and regions
Aligning the bisulfite sequencing reads helps to detect different types of variation
in DNA methylation across genome. Some of known variation in DNA methylation are
listed below [RDBB11].
• Methylation variable position (MVP): A CpG site that shows different methylation
level between different groups. Given recent findings on non-CpG methylation,
potentially all Cs could be MVPs.
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• Differentially methylated region (DMR): A region of the genome at which multiple
adjacent CpG sites show different methylation level. DMRs can occur in many
different contexts, such as:
– iDMR: imprinting-specific differentially methylated region,
– tDMR: tissue-specific differentially methylated region,
– rDMR: reprogramming-specific differentially methylated region,
– cDMR: cancer-specific differentially methylated region,
– aDMR: aging-specific differentially methylated region,
• Variably methylated region (VMR): These regions are defined by increased variabil-
ity rather than gain or loss of DNA methylation.
• Allele-specific methylation (ASM): These are loci or regions that vary in DNA
methylation because of different parent-of-origin, the presence of a polymorphism
or due to a stochastic event.
• Haplotype-specific methylation (HSM): This is a differentially methylated region
that is defined by a set of co-inherited SNPs (a haplotype).
In Tables 1.1, 1.2, and 1.3 we gather a list of existing methods to find differentially
methylated loci or regions with a brief description of their features.
Different high-throughput sequencing techniques are used to quantify the methyla-
tion state of a specific bisulfite-treated locus at single nucleotide resolution. Discovering
the association between the cell mixture methylation profiles and a cancer type is a well
studied area in EWAS. Some methods identify the differentially methylated Loci (DML)
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- Likelihood ratio test
- Bisulfate sequencing data
[BJMV14]
MethylKit





- Emperical bays model
- Z-test
- DNA methylation array
[PO14]
DMAP
- Mixed statistical test approach
- Fisher exact test





- Bisulfate sequencing data
[FCW14]
Table 1.1: Various methods for finding differentially methylated loci.
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- Binary segmentation based approach
- 2D-KS test
- Bisulfate sequencing data
[JKB+15]
BSmooth
- Smoothing based approach
- Log-ratio test
- Bisulfate sequencing data
[HLI12b]
Biseq
- Smoothing based approach
- Hierarchical testing
- Bisulfate sequencing data
[HDK13]
Bisulfighter
- HMM based approach
- Log-ratio test









- Bisulfate sequencing data
[DS14]
Table 1.2: Various methods for finding differentially methylated regions based on previ-
ously identified differentially methylated loci.
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Category Software Description Ref
DMR
DMRseq
- Regression based approach
- FDR is controlled using [BH95]




- likelihood ratio test
- Bisulfate sequencing data
[WCZ+16]
Epipolymorphism
- using epipolymorphism statistic
- high rate of epipolymorphism
- Bisulfate sequencing data
[LCM+12b]
ProbeLasso
- gather neighboring significant loci
- feature2
- DNA methylation array
[BB15]
QDMR
- Entropy based approach
- using a methylation probability model
- Platform free input data
[ZLL+11]
DMAP
- Mixed statistical test approach
- Fisher exact test
- Bisulfate sequencing data
[SCRM14]
swDMR
- Mixed statistical test approach
- Integrated multiple hypothesis tests
- Bisulfate sequencing data
[WLJ+15]
Table 1.3: Various methods for finding differentially methylated regions without finding
differentially methylated loci.
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between two groups [AKL+12,CHL+13,HCH13,SWZ+12,SW12,SW13] and some oth-
ers identify differentially methylated regions (DMRs) that are associated with cancer or
any other disease [ELC+06, ILAC+08a].
In Section 1.2 we review different experimental methylation profiling methods ei-
ther report the ratio of methylated and unmethylated CpGs within sample per loci or the
number of methylated and unmethylated reads per loci.
The ratio of methylated and unmethylated reads per loci is used to derive the
marginal methylation percentage. In most of studies, the mean of marginal methylation
percentage within a phenotypic group is considered to identify DMLs or DMRs [MSS14,
LGBA+13,AKL+12,BB15,DS14,HLI12a,ZLL+11]. There are studies, using array data
or sequencing data, in which other statistics like the variance of marginal methylation per-
centage is used to identify DMLs or DMRs [PO14, TGJ+16, AW13, RSS+16, SWC+17].
Many methods that concentrate on finding DMLs model read counts with a beta-
binomial regression model [PFRS14,FCW14], while there are studies that do not consider
within group variation [MSS14,LGBA+13,AKL+12,BB15,DS14,HLI12a,ZLL+11]. All
of them estimate the mean and variance of read counts per loci and suffer from the fol-
lowing issues:
• High-dimensionality: in order to find DMLs they check every CpG site for com-
puting the desired statistics. This bring a huge computational cost for proposed
methods,
• Low sample size: to test the significance of a differentially methylated loci, a large
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sample size is needed. Also, in order to model the count data per loci, the pre-
dictions will lose their accuracy, because the methods do not account for spatial
correlation across genome,
• Interpretability: a single loci doesn’t have an epigenetic effect, and biochemical
changes in multiple locations might have an epigenetic effect on the expression of
corresponding genes. This means that differentially methylated regions are more
biologically relevant than a single loci.
Methods like [HLI12a, JML+12a, BB15, JKB+15, HSR15, WCZ+16] find DMRs
by chaining DMLs in order to obtain inference over regions. But, the significance testing
procedure in these methods faces challenges, and in particular they don’t have any control
on the false discovery rate (FDR) at the region level. The last category of methods, find
DMRs using a region-based statistic. A hidden Markov model based method also de-
fine differentially methylated regions [SM15, STM14] based on the methylation profiles
explained above. These methods mainly have the challenge of finding DMR boundaries
across genome.
Besides, the current epigenome studies face two main challenges. First, comparing
the methylation profiles of a cell-type population at single nucleotide resolution does not
completely reflect the heterogeneity of DNA methylation modifications of single cells
within the population. The spatial correlation information of the methylation status of
adjacent CpGs is lost and only distribution of methylation status at single nucleotide res-
olution is reported. As shown in Figure 1.2 changes in the methylation pattern of single
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Figure 1.2: Methylation percentage per loci does not reflect the changes in the underlying
pattern. Black and white circles shows methylated and unmethylated CpG sites respec-
tively. Red circles represent start and end loci of selected region.
cells within a sample does not reflected by its methylation percentage per loci. Second, in
order to call differentially methylated regions between different tissue types, i.e normal
and tumor samples, we might face the tumor cell impurity because of inaccurate tissue
sampling. This means there might be normal cells within tumor samples when tumor
samples are collected. The impurity add some noise to the methylation information and
complicates the process. This raise the need to infer the cell mixture more accurately.
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1.4 Research contribution
In this dissertation, we develop two computational models to (i) reconstruct the
underlying methylation profiles of normal and tumor samples, and (ii) detect regions with
significant difference in their methylation profiles. These models are briefly outlined
below and provided in detail through next chapters.
1.4.1 Reconstructing underlying methylation patterns using bisulfite-
converted sequencing data
In chapter 2, we propose a method called methylFlow to infer the underlying
methylation patterns and calculate their abundances across genome. It incorporates the
spatial correlation between methylated sites and low coverage regions to improve its per-
formance.
1.4.2 Finding regions with significant difference in their methylation pro-
files between normal and tumor samples
In chapter 3, we propose a method called MCFDiff to find regions that their methy-
lation profiles are significantly different in normal and tumor samples. It uses the patterns
inferred by methylFlow and their abundances. we systematically consider tumor content






2.1 The general problem of DNA methylation composition
While single-cell methods to sequence bisulfite-converted DNA are currently under
development [SLA+14b], the most reliable current method to measure DNA methylation
at the base-pair level across the entire methylome is to bisulfite-convert and sequence
DNA from a population of cells. A number of existing computational methods may then
be used to calculate the percentage of DNA fragments that harbor a DNA methylation
modification at specific genomic loci [HLI12b]. In many normal human tissues, for ex-
ample, these percentages vary from the expected levels in a population of diploid cells
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with identical DNA methylation modifications: 100% (where all cells in the population
are methylated at a specific locus), 0% (where all cells in the population are unmethy-
lated) or 50% (where only one chromosome in all cells in the population are methylated).
For example, in the normal colon methylome, the majority of the methylome is partially
methylated at a level of roughly 70-80% [HTB+11]. Similar patterns are observed in
other human tissues [TBM+14], and tissues in other eukaryotes.
An obvious observation that follows from this is that cell populations in normal
tissues are composed of epigenetically heterogenous cells. Furthermore, when comparing
DNA methylation across different tissues, for example, colon normal tissue and colon
tumor, Figure 2.1, or a population of stem cells to a population of somatic cells, e.g.,
fibroblast [LPD+09], differences in DNA methylation percentages at a specific locus is
indicative of a shift in the epigenetic composition of these cell populations.
Computational and statistical methods to study the epigenetic composition of cell
populations have been proposed based on the analysis of DNA methylation modifications
at multiple consecutive genomic loci spanned by single sequencing reads [LCM+12b],
where they analyzed DNA methylation modifications at each group of four contiguous
CpG dinucleotides using sequencing reads that span all four CpGs. They then calculate
the proportion of reads compatible with each of the 24 possible DNA methylation mod-
ifications over these four positions. They summarize these 24 proportions to define the
epipolymorphism of each set of four contiguous CpGs.










Figure 2.1: Differences in DNA methylation percentage at a given locus are indicative
of a shift in the epigenetic composition of cell populations. (a) Base-pair level DNA
methylation percentage estimate for three colon tumors and paired normal tissue (Figure
from [HTB+11]). (b) Different shifts in the epigenetic composition of the cell population
in a tissue lead to identical marginal differences of DNA methylation percentage at the
base-pair level.
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epigenetically across different tissues, they only provide a general summary of the epige-
netic composition of these cell populations. For instance, distinguishing between the two
types of cell population shifts illustrated in 2.1 is limited to those differences observed
over four contiguous CpGs. In order to perform a comprehensive analysis of these cell
population shifts, the ability to reconstruct cell-specific methylation patterns over longer
genomic spans is required.
In this chapter we present methylFlow, a novel computational method to recon-
struct cell-specific patterns using reads obtained from sequencing bisulfite-converted
DNA based on network flow algorithms. We report on a simulation study character-
izing the behavior of our method. We then present an application of this method us-
ing ultra-high coverage targeted sequence in a colon cancer study [HTB+11], and on
whole genome sequencing of fully differentiated B-cells and KSL and CLP progenitor
cells [KKTM+13]. We also perform a validation study using bisulfite-converted DNA
from single-cells [SLA+14b]. We believe that this method will allow for increased un-
derstanding of the role of epigenetic heterogeneity at the cell population level in gene
regulation. This work is in press in Bioinformatics [DMCB16].
2.2 methylFlow algorithm
Our method uses sequencing reads from bisulfite converted DNA to reconstruct het-
erogeneous cell populations by assembling cell type-specific methylation patterns span-
ning multiple CpGs from read overlaps (Figure 2.2). It jointly reconstructs these methy-
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lation patterns and quantifies their abundance in heterogenous cell populations.
Our method assumes a set of aligned reads from a bisulfite converted DNA sequenc-
ing run sorted by genomic starting location. For this paper, we only analyze on cytosine
methylation so that each CpG overlapped by a given aligned read can be determined to
be methylated (M) or unmethylated (U). Each aligned read r is thus associated with a
starting genomic position lr and a specific methylation pattern over the CpGs it spans.
The latter is defined by set pr = {〈offseti,mi〉} where offseti specifies the location of the
CpG based on the read start position l and mi ∈ {M,U} specifies the methylation status
of the ith CpG covered by the read.
2.2.1 Overlap graph
Following existing methods from viral population reconstruction [EPM+08], we
build a read overlap graph based on read starting location and compatibility of methylation
patterns. Read overlap graph Go = {Vo, Eo} contains a node (lr,mr) for each aligned
read r (as described above) originating from position lr with methylation pattern mr. A
directed edge (r, r′) between from source node r to target node r′ is included in the graph
if it satisfies the following:
1. lr < lr′: the starting position of the source is to the left of the starting position of
the target, and
2. methylation patterns mr and mr′ are equal on overlapping cpgs (if any), and
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Figure 2.2: Overview of methylation pattern estimation: We assume that samples are
obtained from cell populations (top left) that are epigenetically heterogeneous as deter-
mined by distinct CpG methylation patterns along a genomic region (top right). Recon-
struction is based on the overlap of bisulfite converted reads to a reference genome (bot-
tom left). Read overlaps and methylation calls are used to define a region graph (bottom
right). Based on coverage (the number of reads originating in each region), a minimum
cost network flow problem to estimate the number and abundance of methylation patterns
(paths in the graph).
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3. there is no path between r and r′ in the graph unless this edge is present, so there
are no paths between ancestors of the target node.
We denote the number of reads originating at position l with methylation pattern m
as cl,m. This is the same construction as [EPM+08] with methylation patterns taking the
place of variants in reads obtained from virus sequencing.
2.2.2 Coverage normalization
To build a statistical model, we first normalize the coverage in the overlap graph to
account for variability introduced by non-uniform sequencing coverage and copy number
variations. The number of reads for node (l,m) is normalized as follows:
Let cl =
∑
m cl,m be the total number of reads originating in position l, and let
µ = medianlcl across a connected component of the graph. The normalized number of
reads for node (l,m) is defined as yl,m =
cl,m
cl
× µ. After normalization, all positions l
have total normalized number of reads equal to s.
2.2.3 Region graph
Building a statistical model over position-specific coverage is difficult due to vari-
ability in low coverage experiments. To alleviate this issue, we use the fact that DNA
methylation modifications show high spatial consistency [HP75] and convert the read
overlap graph Go to a region graph G = {V,E} by collapsing non-branching paths in the
overlap graph Go so that nodes now span multiple genomic loci. The total, normalized,
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number of reads originating in region v ∈ V is defined as yv =
∑
(l,m)∈v yl,m. We define
the starting position lv of region v ∈ V as minl{(l,m) ∈ v}, i.e., the smallest position l
over nodes of the overlap graph Go contained in region v. We also merge read methyla-
tion patterns into region methylation patterns (since by definition these are consistent), so
that each region also defines a methylation pattern pv =
⋃
(l,m)∈vm.
To complete the region graph we add a source node s connected to every region in
the graph without an incoming edge, and a sink node t connected to every region in the
graph without an outgoing node. Cell-specific methylation patterns p are defined by paths
in the region graph from start node s to end node t each with a specific methylation pattern
defined by the methylation patterns of the regions in the path. We denote the abundance
of cell-specific methylation pattern p, equivalently path p, as θp.
Given this notation, the total abundance of methylation patterns consistent with
region v ∈ V is given by the sum of the abundances of paths that include v:
∑
{p:p3v} θp.
Note that by construction the following three sets are equal
{p : p 3 v} =
⋃
{u:(v,u)∈E}




{p : p 3 (u′, v)}
This just states that the set of paths going through node v ∈ V can be enumerated
as the union of all paths going through all outgoing edges {(v, u) ∈ E}, or as the union
















We will use relationship 2.1 in our estimation procedure.
2.2.4 Statistical model
We introduce a statistical model that motivates our reconstruction algorithm based
on fitting the normalized observed number of reads yv originating in region v ∈ V of the
region graph. This is similar to statistical models used in viral population reconstruction
methods [EPM+08], or RNA-seq [BJMV14].
Our goal is to estimate Eyv, the expected number of reads originating from region
v as a function of the abundances θp of unobserved methylation patterns p. In order to
do so, we need to define the effective length of region v in pattern p which we denote
`vp. Since every methylation pattern p corresponds to a path p through region graph G,
the effective length of region v ∈ V within pattern p is determined by outgoing edge
(v, u) ∈ p. Specifically, the effective length `vp = `vu = lu− lv for every path p such that
(v, u) ∈ p and lu and lv are the starting positions of regions u and v respectively. As Eyv
corresponds to the expected number reads originating in region v, it is proportional to the
effective length of the region.













Using a regularized method of moments, we estimate parameters θp corresponding















where p ranges over all paths in the region graph and λ is a regularization term.
This formulation is similar to the IsoLasso [LFJ11] model defined for RNA-seq transcript
assembly and quantification. In our case, we use absolute loss to implement robust median
regression (instead of least squares regression).
The regularized method of moment estimator yields a linear optimization problem
over a large number of unknowns, namely, the number of possible paths through the
region graph G = (V,E). We follow the idea behind the FlipFlop method [BJMV14]
developed for transcript assembly from RNA-seq data using regularized loss functions.
We do not explicitly solve over all possible paths p, instead we introduce variables fvu for
each edge (v, u) ∈ E defined as fvu =
∑
{p:p3(v,u)} θp and rewrite the method of moments














with regularization term λ
∑
p θp in Equation 2.2 rewritten using edge variables fut








To ensure variables fuv correspond to the sum of methylation pattern abundances,
equivalently paths, that include edge (v, u), we add the following constraints which follow







Since we are using absolute deviation as our method of moments estimating crite-
rion we obtain a linear optimization program with linear constraints. It corresponds to a
network flow problem where variable fuv is the flow assigned to edge uv and constraints
in Equation 2.4 correspond to standard network flow balance constraints.
Our software takes as input a set of aligned bisulfite-converted reads which may
be obtained using existing bisulfite-aware read mappers [KA11, HLI12b]. It assumes the
input is in SAM files as produced by the Bismark [KA11] aligner. We solve the dual
problem [Lue73] of the above linear optimization problem using the GLPK [Mak08]
linear programming (LP) solver and the LEMON [DJK11] C++ library to represent
and manipulate the read overlap and region graphs. Source code is freely available at
http://github.com/hcorrada/methylFlow as C++ source code, and includes a small R pack-




Error metrics are based on first matching each simulated pattern with one or more
of the patterns estimated by our method, and then determining error in abundance esti-
mates or methylation calls for the estimated patterns based on this matching. We note
that these error metrics are only applicable in simulation settings where true patterns and
abundances are known.
To match estimated patterns to simulated patterns we build a bipartite graph
({S, T}, E): each node in S represents simulated pattern with abundance θi while set
T has a node for each estimated pattern with abundance θj . Each edge connecting node
i ∈ S to node j ∈ T has weight wij equal to the total number of methylation call differ-
ences between patterns i and j. wij equals the number of overlapping CpGs with different
methylation status plus the number non-overlapping CpGs. wij is zero if pattern i ∈ S
exactly matches pattern j ∈ T in all their methylation calls and have no non-overlapping
CpG sites. We then solve a minimum weight matching problem on the bipartite graph so
that the matching node of simulated pattern i is the estimated pattern j in set T which has
the smallest weight wij among neighbors of node i. Below we use indicators xij equal to
1 if i and j are matched and is equal 0 otherwise.
To better understand the behavior of error metrics, we report errors for multiple
thresholds based on weights wij . If the number of methylation call errors between es-
timated and simulated patterns is above the threshold, then the match is not used when
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calculating error metrics below.
2.3.1 Abundance error
Based on the resulting matches for each estimated pattern, we determine a score to
evaluate how well our algorithm predicts the average abundance of patterns as follows:











This error metric shows how well our algorithm predicts the abundance of simulated
patterns. Since the abundance of patterns are different in different settings, we compare
the abundance of true patterns by their matched estimated patterns and scale them by the
abundance of true patterns. This gives us the relative error between the abundance of true
and estimated patterns.
2.3.2 Methylation call error
Our second error metric evaluates the prediction of methylation calls for estimated
patterns. We use the same bipartite graph and same matching problem we did for calculat-
ing the average abundance error. Hence, based on our bipartite graph and the matches for
every simulated pattern, we determine a score to evaluate how well our algorithm predicts
the methylation patterns as follows:
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The average methylation call error shows how well the estimated patterns are
matched to true patterns. It is equal to the average number of methylation status er-
rors between simulated and their matched estimated patterns. Since we are using these
weights to discard matched patterns, we expect that the methylation call error is less than
the corresponding threshold.
2.3.3 Minimum cost network flow error
Our third error metric evaluates performance based on both methylation call error
and pattern abundance estimates. In this metric there is no threshold is used to filter
pattern matches between simulated and estimated patterns. Instead, we run a minimum
cost network flow problem that matches every true pattern to a set of estimated patterns
on the same bipartite graph.
However, we add constraints such that the sum of outgoing flows from every node
in true pattern set is equal to the abundance of corresponding true pattern and the sum
of incoming flow to every node of estimated pattern is also equal to the abundance of
corresponding estimated pattern. fij is the amount of flow goes from true pattern i to
pattern j such that the sum of all fij s are minimized. Then we compute the expected
methylation call error by multiplying the probability of pattern i and j being matched, i.e.,


































Minimum cost flow result
Figure 2.3: Bipartite graph built to solve a minimum weight matching between simulated
patterns and estimated ones(Left), Minimum weight matching solution (Right)
The cost of our network flow in our bipartite graph is equal to sum of the weights of every
pair (i, j) multiplied by the amount of the corresponding flow. This metric evaluates how
well our algorithms predict both methylation calls and the abundances.







fij = θi, ∀i ∈ S∑
i
fij = θj,∀j ∈ T
fij ≥ 0,∀i ∈ S,∀j ∈ T
Here fij is the amount of flow from node i ∈ S to node j ∈ T and corresponds to
the fraction of the abundance of simulated pattern i matched to estimated pattern j. The
cost of our network flow in our bipartite graph is equal to sum of the weights of every pair
(i, j) multiplied by the amount of the corresponding flow. It is a measurement to evaluate
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how well our algorithms predict both methylation calls and the abundances.
2.4 Simulation study
We performed a simulation study to evaluate the performance of our algorithm
based on how well it predicts the number of cell-specific patterns, how many methylation
calls are reconstructed correctly in each pattern and how well it predicts the abundance of
each pattern.
Our simulation has two separate steps: first, we simulate n cell-specifc methyla-
tion patterns over a genomic region and then simulate the sequencing process to produce
short reads using uniform samples across the simulated pattern. We call these simulated
patterns as true patterns.
2.4.1 Simulating true patterns
We use three different settings of increasing difficulty to simulate the cell-specific
true patterns:
• Simple: Number of true patterns is n = 2, one with 75% of abundance and the
other with 25% of abundance. The two patterns share almost no CpGs with the
same methylation status.
• Moderate: Number of true patterns is n = 4, with 15%, 15%, 30% and 30% of
abundances respectively. Patterns share a moderate number of CpGs with the same
methylation status.
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• Hard: Number of true patterns is n = 10, all with 10% of abundances and only a
small number of CpGs have distinct methylation status across patterns.
Methylation patterns are simulated such that nearby CpG sites are likely to have
similar methylation status based on their genomic distance. Specifically, two CpG sites
with distance d have the same methylation status with probability:
f(d) = 1− 1
1 + e−10×(d−corrDist)
(2.5)
where corrDist = 20 is a parameter that controls methylation status correlation between
two consecutive CpG sites. To simulate a pattern, the methylation status of the first CpG is
set uniformly at random, and each subsequent site is set to the same status as the previous
CpG with probability f(d), otherwise it is set uniformly at random. CpG locations for
1750 CpGs were obtained from a whole genome bisulfite sequencing dataset [10].
2.4.2 Simulating short reads
For simulating the sequencing process, we randomly select a pattern with proba-
bility proportional to its abundance. Read start position is uniformly chosen at random.
Every CpG site is sequenced without any error with probability 1 − error. If parameter
error = 0, then methylation pattern of every short read is exactly the same as its true
pattern. A total of coverage×dnaLength
readLength
short reads are generated in each simulation setting.
Parameters for coverage, short read length, number of CpG sites in the simulation
region are varied over a specified range for each simulation setting as we test the behavior
of the algorithm as a function of these three parameters. Otherwise, these parameters are
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held to constant values 20 for coverage, 100 for number of CpGs, and 70 bp for short read
length.
When testing the effect of each of these parameters on the performance of our algo-
rithm, coverage is varied from 5 to 20, short read length varies from 50 to 250, the number
of CpG sites varies from 75 to 150.
2.5 Results
2.5.1 Simulation results
To evaluate the performance of our algorithm, we need to consider the average
abundance error and average methylation call error simultaneously as abundance errors
may increase as more stringent thresholds are placed on methylation call error. In Fig-
ure 2.4 (A-C) average abundance error versus average methylation call error is shown
for the moderate simulation setting as we test the effect of coverage, number of CpGs
and read length on the reconstruction algorithm. We show the effect of using different
methylation call error thresholds on matched patterns and the error metrics.
We observed that abundance error decreases and methylation call error increases as
read length and coverage increases. Increasing coverage and read length help to decrease
the problem complexity and have a more accurate reconstructed pattern. In particular,
we observed that while doubling coverage from 5x to 10x significantly decreases error,
doubling coverage from 10x to 20x has much less pronounced effect. Increasing the
number of CpGs increases the complexity of the problem and both average abundance
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Figure 2.4: Average abundance error vs. average methylation call error in different set-
ting of simulation and various thresholds in moderate complexity of patterns. Points
correspond to increasing threshold on methylation error between matched patterns. Pan-
els show the effect of different (A) coverage (B) number of CpG sites, and (C) short read
length on error. (D) Average abundance error vs. average methylation call error in dif-
ferent simulated pattern complexity with fixed coverage, number of CpG and short read
length.
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and average methylation call error increase. In this Figure 2.4D, CpG, read length and
coverage are fixed, while pattern complexity is varied. Methylation call error and average
abundance error increases as the complexity of patterns increases.
Figure 2.6 shows the minimum cost network flow error metric for our three simu-
lation settings as a function of coverage, number of CpGs and read lenght. By increasing
coverage and read length, as we expect, the complexity of reconstruction decreases and
the error decreases consequently with error decreasing sharply from 5x to 10x coverage,
with slower decrease after that. Since we are reading CpG positions from a real data set,
increasing the number of CpG sites are expanding the genomic region but the density of
CpG sites remains almost the same. Hence, we see a slight increase in the error.
Our algorithm is less dependent on the number of CpGs. The performance of our
algorithm slightly decreases by increasing number of CpGs and that is mainly because
of the extension in the length of reconstructed region. Coverage has more significant
effect on the performance of our algorithm. We see more errors in low coverage regions.
Also our algorithm performs better if we could have longer sequencing reads and less
ambiguity between cell-specific patterns.
We also evaluate sensitivity of our algorithm to error in sequencing CpG methyla-
tion status. Figure 2.5 shows that the minimum cost flow error increases by increasing
the probability of noise. Note that when the noise level is 50, i.e p(error) = 0.5 in se-
quencing, then the short reads are random, and thus the output will be random, i.e., the
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Figure 2.5: (Left) Sensitivity to the noise level in the input. Minimum cost flow error
for various noise levels, probability error in sequencing, of the input data. (Right) Sen-
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Figure 2.6: Minimum cost flow (MCF) error for three different simulation settings with
different complexity. (A) The effect of coverage on MCF error. (B) The effect of the
number of CpG sites on MCF error. (C) The effect of short read length on MCF error.
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trols the number of estimated patterns. As can be seen in Figure 2.5, the methylFlow
algorithm is not sensitive to regularization parameter in a wide range of λ. In particular,
methylFlow achieves consistently good performance with λ varying from 0 to 100 for
different types of simulated data. This is an interesting property because we do not need
to tune the regularization parameter very precisely in the real data sets.
2.5.2 Single cell results
We also evaluated our algorithm using a single-cell bisulfite sequencing (scBS-seq)
dataset [SLA+14b]. Smallwood et al performed scBS-Seq on mouse embryonic stem
cells (ESCs) cultured either in 2i (2i ESCs) or serum (serum ESCs) conditions to de-
termine whether scBS-Seq can reveal DNA methylation heterogeneity at the single-cell
level. In order to evaluate the performance of our algorithm, we ran our algorithm sepa-
rately on 2i and serum single cell data sets that were aligned to GRCm38 mouse genome
using Bismark in single-end mode. We observed that our algorithm reconstructed a sin-
gle pattern for 93% of the regions covered and obtained two patterns for 6% of covered
regions. We also ran methylFlow on a mixture of 2i and Serum samples. For 79% of
regions, methylFlow recovered exactly the same number of patterns as expected from
the mixture. For 17% of the regions, methylFlow recovered one fewer pattern than ex-
pected from the mixture. This result suggests that methylFlow is capable of identifying
long-range methylation patterns in a epigenetically heterogeneous cell population. Un-
fortunately, coverage for single-cell sequencing data is too low to reliably estimate our
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algorithm’s performance in estimating the abundance of patterns in a heterogeneous cell
population.
2.5.3 Whole genome bisulfite sequencing results
We also applied our method to a whole genome bisulfite sequencing data on mouse
wild-type activated B cells and mouse CLP and KSL cells [KKTM+13] aligned using
bismark v0.11.1. The length of short reads are 50 bp and all analyses were done relative
to the mm10/GRCm38 assembly of the mouse genome. We were able to reconstruct
cell-specific methylation patterns with median length 200 to 750bp (Figure 2.7). Patterns
longer than 750bp were reconstructed in each sample.
Again, we report the performance of our method using the marginal methylation
percentage of estimated patterns at CpGs to those obtained from short reads directly. a
Figure 2.7, panels C and D, shows that marginal methylation estimates from patterns to
those obtained from short reads (correlation 0.92 and 0.91).
2.5.4 Targeted bisulfite sequencing
We applied our method to data from a targeted bisulfite sequencing experiment on
three colon tumors and matched normal tissue [HTB+11]. Read lengths in this dataset
are either 73bp or 80bp, and we used the provided read alignments with a post-processing
script (available upon request) to resolve strand-aware methylation status as reported by
the alignment tool before constructing the read overlap graph. We were able to reconstruct
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cell-specific methylation patterns with median length 110 to 200bp. Patterns longer than
350bp were reconstructed in each sample.
Since the true cell type methylation patterns are not known, the error metrics pre-
sented in Section 2.3 are not applicable. In real datasets, we instead report performance by
comparing marginal methylation percentage of estimated patterns at CpG level to those
estimated from short reads directly. Since we are not using this information in recon-
structing patterns, similar beta value (marginal methylation percentage) could evaluate
the performance of our method.
As illustration of the type of inference provided by our method, we show in
Figure 2.8 the patterns estimated for a differentially methylated region. We obtained
the most differentially methylated region in chromosome 13 using bumphunter soft-
ware [JML+12b]. The figure depicts the estimated patterns in every sample along with
their abundances in this hyper-methylated region. We observed that populations in tumor
are more heterogenous than in normal (which itself is heterogenous to a small degree),
and that dominant patterns in the normal population are present in the tumor population.
2.6 Discussion and conclusion
We have presented an algorithmic method to reconstruct cell-specific methylation
patterns using overlap and coverage of sequencing reads of bisulfite-treated DNA. Our
method allows researchers to probe intra-cellular epigenomic heterogeneity from a stan-
dard sequencing experiment of pooled cells. This work opens new avenues in the analysis
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Figure 2.7: Pattern estimation in targeted bisulfite sequencing of three colon tumors and
matched normal tissue in chromosome 13. (A) Length distributions of reconstructed cell-
specific methylation patterns. (B) Distributions of the number of CpGs per reconstructed
cell-specific methylation patterns. (C and D) CpG methylation percentage estimated from
reconstructed cell-specific methylation patterns (pattern methyl Percentage) vs. observed
CpG methylation percentage (region methyl Percentage) for a single tumor sample and
matched normal.
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Figure 2.8: Differentially methylated region between colon tumors and matched normal
pairs with corresponding patterns and their abundances across different samples. The
top panel shows the marginal methylation percentage and the average curve of marginal
methylation percentage as estimated by bumphunter. The bottom panel depicts the methy-
lation patterns of samples. Blue bars represent the abundance of corresponding patterns.
The abundances are normalized by sum of the abundances of all patterns in selected re-
gion.
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of epigenomes as statistical extensions to our work here can start addressing questions of
differential presence of cell-specific methylation patterns across phenotypes of interest,
and begin to understand specific changes in the epigenomic complexity of cell communi-
ties.
Some cell-devoncolution methodologies like methylPurify [ZZW+14] uses regions
with bisulfite reads showing discordant methylation levels to infer tumor purity from tu-
mor samples alone. They do not assume any genomic variation information or prior
knowledge from other datasets. Some restrictions in their method is that they infer the
fraction of normal cells within tumor samples by assuming that there are only two com-
ponent of normal and tumor cells. They also detects differentially methylated regions
from tumor and normal cell lines, under assumption of homogeneous tumor and normal
cell lines. Since they only consider CpG sites, they expect to see consistent methylation
level within short intervals(300bp). [HAK+12] also present a statistical method to infer
the distribution of different cells in a subpopulation and similarly, methylMix [Gev15]
developed a computational algorithm to identify differentially methylated genes that are
also predictive of transcription. The two latter methods used the Illumina Infinium Hu-
manMethylation 27k or 450k BeadChip.
Our simulation study shows that our methodology is sensitive, as other similar
methods for sequencing data, to sequencing depth. Figure 2.4 indicates that that our
approach works well at depths of 10x or greater. Our software outputs total coverage per
connected component in the region graph. In practice, regions that have less than 10x
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average coverage should be removed for downstream analysis.
While we have not applied our method to Reduced Representation Bisulfite Se-
quencing data [MGB+05b], it should directly apply as presented in this manuscript, un-
der the same caveats regarding coverage discussed above. RRBS is designed for high
density regions, and usually tends to yield higher coverage than WGBS, which makes it
suitable for our methodology. Our method requires single fragment methylation calls as
input as provided by sequencing assays, which makes it unsuitable for array-based assays,
tiling [ILAC+08b] or based on Bisulfite conversion as signal in this case depends on the
number of methylated and unmethylated fragments in a pool of cells [BBT+11]. While
we believe that our normalization method somewhat alleviates coverage biases stemming
from sequence or amplification effects, a normalization model that incorporates relevant
technical covariates could significantly improve any instability in our estimation method
stemming from coverage biases.
As presented here, our method only performs reconstruction of patterns for single
samples (e.g., a single tumor sample). A consideration for future work is to establish an
algorithm that jointly estimates cell-specific methylation patterns across samples. How-
ever, our graph matching procedures described in Section 2.3 can be used to associate
estimated patterns across individual samples in subsequent analyses.
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CHAPTER 3




Cells in our body have almost identical DNA sequence since they stem from a
similar single embryonic cell. However, they have different DNA methylation modifica-
tion profile depending on the cell-type, age, disease or other biological states. Different
phenotypic properties in different cell-types and in different tumor tissues (inter tumor
heterogeneity), as well as the subclonal diversity within a cell-type or tumor tissue (in-
tra tumor heterogeneity) correspond to their epigenetic modification profiles within a cell
population. These modifications are not fixed and vary over time [LCM+12a]. DNA
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methylation is identified as one of the most important epigenetic modifications. Variations
in the DNA methylation modification profiles are not consistently reflected by phenotypic
variations while some make distinct phenotypic changes. Studies have found that varia-
tions in methylation levels (hyper-methylation) in promoter-related CpG islands leads to
silencing of downstream tumor suppressor genes in many type of cancers. Furthermore,
instability of epigenome in some regions has been associated with cancer heterogeneity.
This influences the functionality of cells and disease state of the cell-type population as a
result. Therefore, a comprehensive understanding of cell mixture methylation profile and
its association to health and disease, age or other state of interest has become a priority in
epigenome-wide association studies (EWAS).
In this chapter we propose a method, which is called MCFDiff, to find the regions of
differential methylation composition (RDMC). We infer the underlying DNA methylation
patterns within a heterogeneous cell population using methylFlow algorithm, which has
been defined in Section 2.2. We compare the composition of underlying patterns using
a new statistical method. We consider both the underlying patterns of DNA methyla-
tion modification and the abundance of each pattern within samples in our model. Any
significant changes in the abundance, the pattern or both is considered as RDMC.
We improve the prediction of RDMC by applying two different strategies. First,
we employ the reconstructed underlying pattern to retain the spatial correlation of DNA
methylation modifications in cells within a heterogeneous population. Second, regarding
the underlying patterns, we infer the impurity of the cell-type population by leveraging our
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proposed similarity metric, and improve the prediction of RDMC. Both of the strategies
improve false negative rate along as sensitivity and specificity. See Section 3.2 for more
details about MCFDiff method.
We evaluate the accuracy of the proposed method for finding RDMC by comparing
its results with the results of DMRseq method which is introduced in [KCBI17]. We first
evaluate the performance of our method by the simulation. We employ the simulation data
including the simulated patterns for normal and tumor replicates and also the information
of the regions that have different methylation pattern composition. The results discussed
in Section 3.4.1 show the accuracy of our proposed method. In particular, we improve the
sensitivity and specificity along with smaller type I and type II error compared with other
methods. We also evaluate our method using real data. The results given in Section 3.4.2
show that in regions with experimental evidence, MCFDiff performs meaningfully better
than DMRseq in predicting regions with significant change in their DNA methylation
modification.
3.2 Materials and method
3.2.1 Constructing methylation patterns
In our proposed method for finding RDMC, we first use methylFlow algo-
rithm [DMCB16] for reconstructing methylation profiles. Let’s assume we have k
number of normal tissues and their matched tumor tissues. We first use their bisul-
fite sequencing read counts to reconstruct their underlying methylation profiles across
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genome for every tissue. Then, we exploit the composition of inferred methylation
patterns from the first step in the same cell-type population to capture the variation
in composition of patterns, namely their epigenetic profiles. In particular, the re-
sult of running methylFlow is DNA methylation profiles {N1, N2, · · · , Nk} for nor-
mal tissues and {T1, T2, · · · , Tk} for tumor tissues. Furthermore, each tissue profile
P ∈ {N1, · · · , Nk, T1, · · · , Tk} is a set of patterns {pP,1, pP,2, · · · , pP,nP} with their cor-
responding abundances {θP,1, θP,2, · · · , θP,nP} where nP denotes the number of patterns
in tissue profile P .
3.2.2 Similarity metric
Assume a regionR with start position lR and end position eR is given, and our pro-
posed algorithm needs to find if it is a RDMC. RegionR spans DNA methylation profiles
{N1, N2, · · · , Nk} for normal tissues and {T1, T2, · · · , Tk} for tumor tissues. Let methy-
lation profiles {NR1 , NR2 , · · · , NRk } and {TR1 , TR2 , · · · , TRk } be the methylation profiles
of normal tissues and tumor tissues in region R respectively. Furthemore, for each tis-
sue profile P and the selected region R, let {pRP,1, pRP,2, · · · , pRP,nP} be the set of patterns
of profile P in region R, and {θRP,1, θRP,2, · · · , θRP,nP} be their corresponding abundances.
Note that for all 1 ≤ i ≤ nP we know θRP,i = θP,i. Moreover, for the sake of simplicity
we might use pP,i instead of pRP,i.
In order to find RDMC, we measure the pairwise similarity between any
of two profile. For the selected region R and tissue profiles P ,P ′ ∈
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{NR1 , NR2 , · · · , NRk , TR1 , TR2 , · · · , TRk }, we build a wighted bipartite graph GRP,P ′ =
{{SRP,P ′ , RRP,P ′}, ERP,P ′} where each node in SRP,P ′ represents a methylation pattern that
belongs to methylation profile P and each node in RRP,P ′ represent a methylation pat-
tern that belongs to profile P ′. For the sake of simplicity we might use GP,P ′ =
{{SP,P ′ , RP,P ′}.EP,P ′} instead of GRP,P ′ = {{SRP,P ′ , RRP,P ′}, ERP,P ′} in the rest of this
chapter.
The edge from node i ∈ SP,P ′ with methylation patterns pP,i and the abundance of
θP,i to node j ∈ RP,P ′ with methylation patterns pP ′,j and abundance of θP ′,j has weight
wij and equals to the number of overlapping CpGs with different methylation status plus
the number of non-overlapping CpGs divided by the total number of CpGs spanning the
region. The value of wij is equal to zero if both methylation patterns match on their
overlapping region and have not any non-overlapping CpGs.
Then, to measure the similarities between the composition of cell-specific tissue
profiles P and P ′, we solve an optimization problem that captures the variation in com-
position of patterns. Considering the weights of edges in our bipartite graph and the
abundances of every node in SP,P ′ and RP,P ′ , we want to match every node in SP,P ′ to
a set of nodes in RP,P ′ . In other words matching of pP,i ∈ SP,P ′ to a set of patterns in
RP,P ′ represent the changes that happened to pattern pP,i from tissue profile P to patterns
in tissue profile P ′.
In particular, we use MCF error for measuring the difference between any two tis-
sues with methylation profile P and P ′ as follows:
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j=1 fij = θP,i 1 ≤ i ≤ nP∑nP
i=1 fij = θP ′,j 1 ≤ j ≤ nP ′
fij ≥ 0 1 ≤ i ≤ nP and 1 ≤ j ≤ nP ′ ,
where fi,j is the amount of flow from ith node in profile P that represent pattern pP,i
with the abundance of θP,i to the jth node in profile P ′ that represent pattern pP ′,j with
the abundance of θP ′,j . The value of fi,j corresponds to the fraction of the abundance
of pattern pP,i that is matched to pattern pP ′,j . The MCF error between profile P and
P ′ is equal to the sum of the weights of every pair wi,j , multiplied by the amount of the
corresponding flow. Also the sum of the abundance of all patterns in methylation profileP
is equal to one and that is similar to the sum of the abundances of patterns in methylation
profile P ′. We use this metric as our main similarity metric throughout this chapter.
3.2.3 Significance testing methods
In order to measure the similarities between the composition of cell-specific methy-
lation profiles for a given region R, we define a distance-based similarity matrix AR of




ai,j+k =MCFNi,Tj for 0 < i ≤ k , 0 < j ≤ k
ai+k,j =MCFTi,Nj for 0 < i ≤ k , 0 < j ≤ k
ai,j =MCFNi,Nj for 0 < i ≤ k , 0 < j ≤ k
ai+k,j+k =MCFTi,Tj for 0 < i ≤ k , 0 < j ≤ k,
(3.1)
Here,MCFNi,Tj is MCF error between patterns of normal tissueN
R
i and pattern of tumor










Given the distance-based similarity matrixAR for the region of our interest, the sig-
nificance of each RDMC is assessed via a permutation procedure using MiRKAT method.
We run a t-test and use the false discovery rate (FDR) control procedure introduced
by [BH95]. The results show that the accuracy of our method is improved by running
t-test compared to applying MiRKAT (See Section 3.4.1 for more details).
• MiRKAT method: High-throughput sequencing technologies provide a great op-
portunity to improve population-based studies in order to find the association be-
tween population profile and many various outcomes. MiRKAT [ZCC+15] is a
regression-based kernel method to test the association of the human microbiome
and exposure response. It also allows multiple outputs and using different distance-
based scores with the goal of choosing the best distance. It uses a variance-
component score statistic to test for the association with analytical p-value calcula-
tion. We apply MiRKAT to find if there is any association between the methylation
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profiles and the health status of our samples.
• t-test method: T-test provides an analytical framework that is used to assess
whether the mean of two groups are different from each other. We also use t-
test to study the association of DNA methylation profiles of region R in different
samples and desired output, i.e., health status of samples. We apply t-test on the
similarity scores in our distance-based similarity matrix AR. In particular, we run a
t-test to compare the distribution of similarity scores of normal-normal methylation
profiles, i.e., MCFNi,Nj for 1 ≤ i, j ≤ k, and the distribution of similarity scores
of normal-tumor methylation profiles, i.e., MCFNi,Tj for 1 ≤ i, j ≤ k. We use




In order to evaluate our method, we first simulate synthetic data and compare
MCFDiff with other methods. Consider a DNA methylation profile P ∈ {N1, · · · , Nk}
from a heterogeneous normal tissue sample, such as a colon tissue. It contains nP number
of different DNA methylation patterns such as pP,i for i ∈ {1, · · · , nP}. For the simu-
lation studies, we first set the methylation profile of a normal tissue to P , i.e. the recon-
structed methylation patterns of a normal sample that we get from running methylFlow on
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reduced representation of bisulfite sequencing data of normal colon samples. For a given
number of normal replicates r, we simulate the rest of normal profiles for r − 1 normal
samples and also r tumor samples using methylation profile P . The methylation status of
the CpGs in each pattern is randomly changed for different replicates. The probability of
change in the methylation status is around 0.02 for regions for which the composition of
methylation patterns between normal and tumor replicates is not different. This parame-
ter is called non-RDMC mutation probability. Otherwise, the methylation status of each
CpG changes with a larger probability around 0.8 if the region of interest supposed to be
a RDMC. This parameter is called RDMC mutation probability.
However, we assume that the epigenetic heterogeneity within a cell-type population
is reflected either by variations in methylation patters and initiation of new patterns, or
by changes in the abundance of the methylation patterns. Here, we describe how to make
RDMC by making changes in the abundance of patterns and also in the methylation status
of CpGs for the region of interest. This procedure is slightly modified depending on the
complexity of the corresponding region. The complexity of a region is a notion we use
to measure how distributed are the composition of patterns within a region. We define a
pattern as highly abundant (HA), if the abundance of the corresponding pattern is more
that 15%. Then we count the number of HA patterns within the region of interest and
categorize our regions into two different types:
• Low HA: regions with at most one HA pattern. Algorithm for constructing a
RDMC for “Low HA” regions is described in Algorithm 1.
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• High HA: regions with more than one HA pattern. Algorithm for constructing a
RDMC for “High HA” regions is described in Algorithm 2.
Once the DNA methylation profiles are simulated (original patterns for two cate-
gories of samples containing the regions with differential methylation compositions), we
simulate the sequencing process. The output of this step is a set of short reads with their
alignment information. The length of short reads and the sequencing error are the param-
eters that vary between different sequencing simulation scenarios. We set the error equals
to 1 and the length of short reads is equal to 50 in our simulation studies. Short reads from
this step are used later as the inputs for the evaluation process.
3.3.2 Experimental data
We applied our proposed algorithm on an experimental data from a targeted bisulfite
sequencing experiment (RRBS study) [HTB+11]. The experiment is on three colon tumor
tissues and their matched normal tissues. The length of the reads are 73bp or 80bp long. In
their RRBS study [HTB+11], they introduced the concept of cancer-specific differentially
DNA-methylated regions (cDMRs). They showed large hypomethylated genomic blocks
and small DMRs. Authors further confirmed that these regions distinguish normal tissue
types from each other and also distinguish between normal and tumor tissues. They also
proposed that these cDMRs might be common across various cancer types.
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Algorithm 1 Procedure for constructing a RDMC for Low HA regions.
Input: tissue profileP with methylation patterns {pP,1, · · · , pP,nP} and their abundances
{θP,1, · · · , θP,nP}.
1: for each HA pattern p with abundance θ in tissue profile P do
2: construct a clone of p and call it p′
3: let q be a random number in [0, 1]
4: if q ≤ 1
3
then
5: decrease abundance of p to 2θ
3
and set abundance of p′ to θ
3
6: else if 1
3
< q ≤ 2
3
then
7: decrease abundance of p to θ
3
and set abundance of p′ to 2θ
3
8: else
9: decrease abundance of p to 0 and set abundance of p′ to θ
10: end if
11: change the methylation status with probability equal to the non-RDMC mutation
probability for each CpG in pattern p
12: change the methylation status with probability equal to RDMC mutation proba-
bility for each CpG in pattern p′
13: end for
14: keep the methylation patterns exactly the same for non-HA patterns.
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Algorithm 2 Procedure for constructing a RDMC for High HA regions.
Input: tissue profileP with methylation patterns {pP,1, · · · , pP,nP} and their abundances
{θP,1, · · · , θP,nP}.
1: Randomly select half of HA patterns of tissue profile P .
2: for each selected HA pattern p with abundance θ do
3: construct a clone of p and call it p′
4: let q be a random number in [0, 1]
5: if q ≤ 1
2
then
6: decrease abundance of p to θ
3
and set abundance of p′ to 2θ
3
7: else
8: decrease abundance of p to 0 and set abundance of p′ to θ
9: end if
10: change the methylation status with probability equal to the non-RDMC mutation
probability for each CpG in pattern p
11: change the methylation status with probability equal to RDMC mutation proba-
bility for each CpG in pattern p′
12: end for




We evaluated MCFDiff for finding RDMC on both synthetic and real data.
3.4.1 Synthetic data
Synthetic data was generated (as described in Section 3.3.1) for r = 3 number of
matched normal and tumor samples. the RDMC mutation probability is set to 0.8, and
non-RDMC mutation probability is set to 0.02.
3.4.1.1 Evaluating different approaches for testing the significance
We evaluated the performance of MCFDiff on the generated synthetic data.
MiRKAT and t-test were used to detect regions with significance difference in normal and
tumor methylation profiles. Figure 3.1 demonstrates the distribution of the performance
of MCFDiff based on t-test and MiRKAT by varying different simulation parameters in-
cluding number of replicates, the RDMC mutation probability and non-RDMC mutation
probability.
We compared the area under the ROC curve (called AUC) of MiRKAT and t-test
results for different simulation parameters. In order to compute the accuracy distribution,
we did the experiment 100 times and for more than 1000 regions. Figure 3.1 illustrates
that the average of AUC of ROC curve is higher based on t-test for different simulation
parameters. Table 3.1 summarizes the mean of the performance of MCFDiff in terms of
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sensitivity, specificity, average type I and type II error for more than 1000 regions over
100 times and various number of replicates. T-test shows higher sensitivity and specificity
and lower rate of type I and type II error compared with MiRKATto detect RDMC.
Therefore, in the following analysis, we will use t-test to detect regions with signif-
icant difference in methylation profile of normal and tumor samples.
Number of replicates Number of replicates
RDMC mutation probability RDMC mutation probability





























































Figure 3.1: The performance in terms of AUC mean for different number of replicates,
the RDMC mutation probability and non-RDMC mutation probability in terms of the area
under ROC curve, using MiRKAT or t-test method.
In Figure 3.2, we evaluate MCFDiff by monitoring sensitivity, specificity and
Youden parameter with various threshold in rejecting null hypothesis of t-test. Youden’s
68
Method Sensitivity Specificity type I error type II error
MiRKAT 0.65 0.78 0.19 0.09
t-test 0.96 0.91 0.02 0.05
Table 3.1: MCFDiff performance (sensitivity, specificity, type I error, and type II error)
when using t-test or MiRKAT as the significance testing method
index is equal to sensitivity+ specificity−1 and is used as a measurement for monitoring
the performance of our method. Results confirm that MCFDiff improves the sensitivity
significantly along with higher Youden index for the threshold of 0.01 at rejecting null
hypothesis in t-test method. However, we use FDR control method to control the number








































































































































Figure 3.2: MCFDiff results base on different thresholds in rejecting null hypothesis of
t-test using simulated data.
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3.4.1.2 Different methods comparison
We used synthetic data as described in Section 3.3.1 to compare the perfor-
mance of different methods including DMRseq [KCBI17], DSS [FCW14] and Meti-
lene [JKB+15] with our proposed method, MCFDiff. In synthetic data, RDMC are
defined such that the methylation profile composition is significantly different between
normal and tumor samples. A significantly different region either (i) has different set of
methylation patterns in normal and tumor samples; (ii) the abundance of patterns are dif-
ferent; or (iii) have different set of patterns and different abundances. Note methylation
profile in non-RDMC regions are not significantly different in normal and tumor. We first
explained the details of each method and then compare their performance.
• DMRseq: DMRseq We ran DMRseq using the R package version 1.0.14
from Bioconductor. DMRseq [KCBI17] detects differentially methylated regions
(DMRs) using bisulfite sequencing short reads as input. It provides a permutation-
based approach using a generalized least squares model that considers inter-
individual and inter-CpG variability to generate region-level statistics. These statis-
tics are utilized later in order to find DMRs across genome. FDR control procedure
is used to decrease the number of false positives. All parameters left as default ex-
cept the minimum number of CpGs per DMRs is set to 3 and the gap between them
are kept to be less than 1000 base pairs.
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• DSS: We ran DSS using the R package version 2.28.0 from Bioconductor. It is
based on a Bayesian hierarchical model to model the mean of marginal methylation
percentage per loci. A Wald test is developed to test the similarity of distributions
between samples and to estimate the p-values per loci. Then, DSS detects DMRs
according to a set of criteria that includes (i) minimum number of CpGs in DMRs
(default is 3); (ii) the threshold of rejecting the null hypothesis; (iii) the length
of DMRs (default is 100); and (iv) the minimum number of CpGs rejecting null
hypothesis in the region (considered as 80% of number of CpGs in the region). We
set DSS’s ’smoothing’ parameter to be ”False” in our study according to DSS’s
manual suggestion.
• Metilene: We ran Metilene version 0.2 − 7 downloaded from
http://www.bioinf.uni-leipzig.de/Software/metilene/Downloads/. Metilene is
based on a scoring model in which they use a binary segmentation algorithm and
2D-KS test to find DMRs. Metilene can be run on both RRBS and WGBS data.
The defined DMRs boundaries have a minimum number of CpGs (We set this
parameter to 3) and there are less than 300 base pairs between adjacent CpGs.
In MCFDiff, we use FDR control procedure to limit the rate of false discoveries at
region level. FDR at region level controls the number of regions that do not have signif-
icantly different composition of methylation profiles between normal and tumor samples
and are categorized as RDMC . FDR at loci level controls the number of loci without
significant difference in their marginal methylation percentage between normal and tu-
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mor samples and are considered as DML. Note that FDR control at the loci level doesn’t
imply the FDR at region level.
In Figure 3.3, we investigate the change of sensitivity versus FDR for DMRseq
and MCFDiff with different FDR thresholds; and for DSS and Metilene for with dif-
ferent single-loci level thresholds. It is shown that MCFDiff achieves significantly higher
sensitivity in predicting RDMC than the alternative methods at similar observed FDR lev-
els or alternative single-loci thresholds. The sequencing error rate is 1% in our synthetic
data.
Note that the FDR control is not valid at a region level for DSS and Metilene.
Although higher sensitivity was observed in the simulation study for DSS compared to
DMRseq, individual loci thresholds can not be recognized for corresponding false dis-
covery rate (one must select a loci threshold using default setting or by checking various
thresholds).
In Figure 3.4, we compared MCFDiff and DMRseq using synthetic data with FDR
control rate of 0.01 for various sequencing error rates. (Only MCFDiff and DMRseq can
be compared using the FDR rate). MCFDiff improves both the sensitivity, specificity and
Youden’s index compared to DMRseq.
We claim that the most important advantage of MCFDiff lies in reconstructing the
underlying patterns within a profile and estimate their abundances. This keeps the spatial
correlation information of adjacent CpG sites, since the methylation patterns within a
profile are not reflected completely using the marginal methylation percentage profile.
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Figure 3.3: Comparing the performance of different methods on synthetic data. different
region level thresholds are varied in MCFDiff and DMRseq; different loci level thresh-
olds are varied in DSS and Metilene.
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Sensitivity Specificity Youden
Figure 3.4: Comparing sensivity, specificity, and Youden’s index of DMRseq and
MCFDiff method using synthetic data with different sequencing error rate. The FDR con-
trol rate is set to 0.01. Note that Youden index equals sensitivity plus specificity minus
1.
Figures 3.5 and 3.6 compare the performance of MCFDiff and DMRseq.
Figure 3.5 compares the frequency of CpGs in regions detected by MCFDiff and the
frequency of CpGs in regions detected by DMRseq having similar absolute difference of
average marginal methylation percentage in normal and tumor samples. The results con-
firm that more CpGs with less difference in their average marginal methylation percentage
reported by MCFDiff rather than DMRseq. This confirms our assumption about losing
the methylation profile information by taking the average across loci.
Figure 3.6 compares the frequency of the difference between marginal methyla-
tion percentage in normal and tumor samples for regions with significant differentially
methylated regions in MCFDiff and DMRseq.
The result shows that the number of regions with small difference in their marginal
methylation percentage of normal and tumor samples are higher in DMRseq compared
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Figure 3.5: Comparing the number of CpGs reported in RDMC detected by MCFDiff
to the number of CpGs in DMRs detected DMRseq with similar difference in marginal
methylation percentage of normal and tumor samples. The Y axis is shown at the log ratio
scale.
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Difference of marginal methylation percentage in normal and tumor samples
Histogram of Difference of Marginal Methylation Percentage in Normal and Tumor Samples 
Figure 3.6: Histogram for number of regions detected by DMRseq, MCFDiff, both or
none that are categorized by the average of absolute difference between marginal methy-




We also evaluated our proposed method using RRBS data of colon tumor sam-
ples from [HTB+11]. In their study, they identified multiple cancer-specific differentially
methylated regions.
For the experimentally identified regions, MCFDiff detects RDMC based on the
reconstructed underlying pattern (given by methylFlow). Next, we compared the RDMC
detected by MCFDiff with the results of DMRseq method. Figure 3.8 and 3.7 show
that for cDMRs characterized by [HTB+11] in chromosome 1 and 3 MCFDiff predicts a
larger subset of regions as RDMC while DMRseq predicts a smaller subset of regions
as DMRs. Note that MCFDiff is sensitive to both changes in the methylation patterns of
subclonal cells and changes in their abundance, while DMRseq detects variations in the
marginal methylation percentage of samples.
3.5 Discussion and conclusion
In this chapter we proposed a statistical method to call the regions of differen-
tial methylation composition (RDMC). We inferred underlying DNA methylation pattern
within a heterogeneous cell population using methylFlow and compared the composi-
tion of underlying patterns using a new statistical method that captures the variation in



























Chr3 : 44035500 - 44042000
Figure 3.7: Comparison between DMRseq and MCFDiff method using real data for
known RDMC on region of interest in chromosome 3. Blue and red circles represent
normal and tumor data respectively.
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Figure 3.8: Comparison between DMRseq and MCFDiff method using real data for
known RDMC on region of interest in chromosome 1. Blue and red circles represent
normal and tumor data respectively.
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methylation modification and the abundance of each pattern within our samples in order
to detect the regions with differential methylation composition. Any significant changes
in the abundance, the pattern, or both, is considered as RDMC.
We improved our prediction of RDMC by applying two different strategies. First,
we employed the reconstructed underlying patterns to retain the spatial correlation of
DNA methylation modifications across genome. This information is lost when marginal
methylation percentage is applied. Second, regarding the underlying pattern, we inferred
the impurity of the cell-type population and improved our prediction about RDMC. Both
strategies improved false negative rate along with sensitivity and specificity. The results
in Section 3.4.1.2 confirm that there is a higher sensitivity and specificity rate as well as
a lower rate of type I and type II error using t-test and FDR control procedure for finding
RDMC compared with other methods.
In real life scenario, we don’t know if the methylation profiles of a region has mean-
ingful differences between normal and tumor samples. A meaningful difference would
imply the association of the methylation profiles with the desired output, i.e. health status
of samples. Hence, we used simulation studies to evaluate the performance of our method.
We used the synthetic data including the simulated patterns for normal and tumor repli-
cates and including the regions that have significant difference between their methylation
pattern composition. Figure 3.3 and 3.4 shows the improvement in sensitivity and speci-
ficity along with smaller rate of type I and type II error in our proposed method compared
with other methods. We also evaluated our method using real data. For the experimen-
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tally identified regions, MCFDiff performs better that DMRseq in predicting regions with
significant change in their DNA methylation profiles.
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CHAPTER 4
Conclusion and Future Directions
4.1 Summary of contributions
This dissertation contributes two computational methods to improve our under-
standing on cancer cells dynamics through the analysis of DNA methylation data.
Reconstructing underlying methylation patterns using bisulfite-converted se-
quencing data
We developed a novel computational method, called methylFlow that reconstructs
the methylation profiles at single-cell level and to infer the abundance of underly-
ing clones for different heterogeneous cell populations across genome. The method,
methylFlow, provides an exceptional opportunity to (i) analyze DNA methylation data
at single-cell resolution within a population by inferring the methylation patterns and
their abundances over longer genomic spans, and (ii) profile the dynamics (beginning to
extinction) of methylation changes across different tissues.
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Finding regions with significant differences in their methylation profiles be-
tween normal and tumor samples
We developed a novel computational method, called MCFDiff that utilizes the valu-
able information provided by methylFlow (the methylation profile of underlying clones
and their abundances in a heterogeneous population to capture tissue or disease specific
variations across genome. MCFDiff increases the accuracy of detecting regions with dif-
ferentially methylated profiles by (i) comparing different tissue types and penalizing any
changes in the methylation profiles of underlying clones including the patterns and their
abundances; and (ii) systematically considering the tumor cell impurities that might hap-
pen because of inaccurate tissue sampling. Profiling the changes between normal and
tumor samples utilizing the reconstructed methylation profiles of the underling clones in
different samples help us to discover de novo epigenetic markers and to investigate known
methylation sites or any specific genes of interest.
4.2 Conclusion and future directions
My goal in this dissertation is to study the epigenetic repertoire of a heterogeneous
cell population. With the advance of high-throughput sequencing techniques, we devel-
oped statistical and computational methods to reconstruct the methylation profiles of un-
derlying clones and estimate their abundances within a cell population. We detected
regions with significant differences in their methylation profiles when comparing normal
and tumor samples. The proposed methods can be considered as a computational com-
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plement to second-generation sequencing techniques to gain the information about the
DNA methylation profiles at single-cell single-base resolution. The methylation profiles
of single-cells within a cell-type population, without the limitation of single-cell stud-
ies, provide a great opportunity to compare and analyze the differences between different
tissue types.
This thesis has been restricted to interpreting methylation changes in cancer. An
important area of future research is to integrate methods, which will jointly profile these
aberrations along with methylation changes. We expect that the joint inference of multiple
classes of aberrations will provide more accurate information that can help us to stratify
clonal populations and to better understand the dynamics of cancer genome.
The underlying clonal populations are related by a phylogeny. The inference of this
phylogeny is an important issue that allows us to have a better insight about a tumor. It
can help us to identify where an aberration is acquired or lost. It is of high interest to
investigate whether the joint phylogenetic analysis from different class of aberration is
beneficial to better understand the cancer genome dynamics.
Single cell sequencing is emerging as a promising tool for studying clonal popula-
tions for both genomic and methylation data. For future research (and when the technol-
ogy is more matured, the cost is decreased and the quality of data is increased), a major
area of research could be to develop methods that group cells within a clonal population
in order to infer the underlying methylation profiles. Grouping cells to share statistical
strength will reduce the noise in measurements similar to the idea of jointly inferring the
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clonal population across multiple classes of aberrations.
The inference of clonal population and their phylogeny is an important step in an-
swering fundamental questions about the underlying populations of tumor, their dynamic,
their resistance to different treatments, metastatic potential and the effect of environmen-
tal stimuli. Thus, we see a valuable opportunity in collaborations between computational
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c++ graph template library. Electronic Notes in Theoretical Computer
Science, 264(5):23–45, 2011. 37
87
[DMCB16] Faezeh Dorri, Lee Mendelowitz, and Héctor Corrada Bravo. methylflow:
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